Monitor for the closing of the Microfluidics sale and any updates on the Treeline transaction, as the company continues to execute its strategic consolidation plan. The lack of disclosed deal value limits immediate financial read-through.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Oct 6 $0.7220entry
- T+1 · 6w ago −6.00%α −5.76% · $0.6787
- T+5 · 5w ago −8.74%α −8.60% · $0.6589
- T+20 · 14d ago −15.40%α −12.23% · $0.6108
- T+29 · todayOpen
- T+60 · in 6w Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Standard BioTools announced a definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The transaction is expected to close in approximately 30 days, subject to customary closing conditions. This follows the recent termination of the Multiplex Bio deal and the signing of the Element Biosystems agreement for the Mass Cytometry business, continuing the company's strategic divestiture process.
Key Financial Metrics
Key Facts
- Standard BioTools entered into a definitive agreement to sell its Microfluidics business to ARCHIMED.
- Transaction expected to close in approximately 30 days, subject to customary closing conditions.
- No purchase price or financial terms disclosed in the filing.
- This is the second business divestiture announced within a week, following the Element Biosystems deal for the Mass Cytometry business.
- The company terminated the prior Multiplex Bio agreement and paid a $1.5 million termination fee.
Financial Impact
Purchase price not disclosed; the deal is part of a broader strategic divestiture program.
Risk Factors
- Risk that the transaction may not close within the expected 30-day timeframe or at all.
- Potential for competing offers or termination of the agreement.
- Uncertainty regarding the financial impact given undisclosed purchase price.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001140361-26-038625 |
| Document: ef20083295_ex99-1.htm | 0001140361-26-038625 |
| Document: 0001140361-26-038625-index-headers.html | 0001140361-26-038625 |
| Document: 0001140361-26-038625-index.html | 0001140361-26-038625 |
| Document: 0001140361-26-038625.txt | 0001140361-26-038625 |
Track record
23 reports on LAB
7 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +17.95% at T+20 after the Feb 24, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 16, 2026today 425 Neutral 4/10 Entry price pending
- Nov 16, 2026today 8-K Neutral 3/10 Entry price pending
- Nov 3, 202613d ago 425 Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
- Nov 3, 202613d ago 8-K Neutral 4/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
- Nov 3, 202613d ago Press Release Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
- Oct 22, 202626d ago EFFECT Neutral 4/10 Entry $0.6400 to $0.6056 Now $0.6200 −3.12% ▼ −5.38% −4.85% vs SPY
- Oct 21, 202626d ago S-4/A Bearish 7/10 Entry $0.6500 to $0.6400 Now $0.6200 +4.62% ▲ +1.54% +0.36% vs SPY
- Oct 9, 20265w ago S-4/A Neutral 6/10 Entry $0.6578 to $0.6589 Now $0.6200 −5.75% ▲ +0.17% +0.18% vs SPY
- Oct 5, 20266w ago 425 Neutral 5/10 Viewing Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers